Vistagen has reported positive outcomes from the exploratory Phase IIA trial of PH284 for the treatment of cancer cachexia.
The $90m will be used to launch the second of two pivotal trials examining the company’s therapy for patients living with heart failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback